C ardiovascular disease remains a leading cause of death and disability, responsible for 31% of all deaths.
; and (3) investigate whether sex modifies the relationship between GLS and subsequent cardiovascular events.
See Clinical Perspective

Methods
Study Population
The Copenhagen City Heart Study is a longitudinal cohort study of cardiovascular disease and risk factors. This echocardiographic substudy includes all participants from the fourth Copenhagen City Heart Study examination spanning from 2001 to 2003, who had an echocardiographic examination, including color tissue Doppler imaging (TDI), performed. [15] [16] [17] [18] Figure 1 displays the flow diagram of the study population. Participants with prevalent heart failure (HF) or atrial fibrillation were excluded. GLS was obtained in a total of 1296 participants aged 20 to 93 years. Whether a participant underwent echocardiography as part of the fourth Copenhagen City Heart Study examination was independent of his or her health status and other risk factors. All participants gave written informed consent, and the study was performed in accordance with the second Helsinki Declaration and approved by the regional ethics committee.
Health Examination
All participants underwent physical examinations and a self-administered questionnaire.
Blood pressure (BP) was measured with the London School of Hygiene sphygmomanometer. Plasma cholesterol and blood glucose values were measured on nonfasting venous blood samples. 19 Plasma proBNP (pro B-type natriuretic peptide) concentration was quantified using a processing-independent assay, and an abnormal value was defined as proBNP>150 pmol/L. Definitions of hypertension, diabetes mellitus, and prevalent ischemic heart disease have been previously described elsewhere. [15] [16] [17] [18] 
Echocardiography
Echocardiography was performed using Vivid 5 ultrasound systems (GE Healthcare, Horten, Norway) with a 2.5-MHz transducer by 3 experienced sonographers. All participants were examined with conventional 2-dimensional echocardiography and color TDI. All echocardiograms were stored on magneto-optical disks and an external FireWire hard drive (LaCie, France) and analyzed offline with commercially available software (EchoPac version 2008; GE Medical, Horten, Norway).
Conventional Echocardiography
The 16 standard segments model, as suggested by the American Society of Echocardiography, was used to evaluate regional function. 20 Evaluation of LVEF was made by 1 observer on the basis of the wall motion index score. LV systolic dysfunction was defined as LVEF <50%. 16, 18 LV hypertrophy was defined as LV mass index (LVMI) ≥96 g/m 2 for women and ≥116 g/m 2 for men. 20 LV dilatation was considered present if LV internal diameter at end diastole/height was ≥3.3 cm/m. 20 An M-mode still frame between the tips of the mitral leaflets and the tips of the papillary muscles was recorded in the parasternal longaxis view. If the correct 90° angle to the long axis of the ventricle could not be obtained, 2-dimensional images were used instead to quantify the myocardial thickness and the dimensions of the LV and the left atrium. LVMI was calculated as the anatomic mass 20 divided by body surface area. The mitral inflow velocity curves were measured using pulsed-wave Doppler in the apical position at the tips of the mitral valve leaflets. Peak velocity of early (E) and atrial (A) diastolic filling and deceleration time of the E-wave were measured, and the E/A ratio was calculated.
Color TDI
Color TDI tracings were obtained with the range gate placed at the septal and lateral mitral annular segments in the 4-chamber view. The peak longitudinal early diastolic (e′) velocity was measured, and the average was calculated from the lateral and septal velocities and used to obtain the E/e′. The aortic valve opening and closing were assessed by placing a 2-to 4-cm straight M-mode line through the septal half of the mitral leaflet in the color TDI 4-chamber view and measured directly from the color diagram.
15,21
Speckle Tracking Echocardiography
Two-dimensional speckle tracking echocardiography was performed in the 2-chamber, 3-chamber, and 4-chamber apical views, with an average of 57 frames per second (SD: 4 frames per second). The endocardial border was traced by an automated function that defined a region of interest (ROI) at the end systole. The investigator visually assessed the detected ROI and, if necessary, manually modified the ROI to ensure correct tracking of the speckles. A tracking was satisfactory if it covered the entire cardiac wall from the endocardium through to the myo-epicardial border and if there was a visible motion of the speckles. In case of poor speckle tracking, the ROI was readjusted. A segment was excluded if it did not fulfill the aforementioned criteria or was compromised by a shadow or artifact. In this case, the automatic quality score was also ignored. GLS was calculated as an average peak strain from the 3 apical projections and the ROI set to cover the entire LV. If speckle tracking could not be obtained from a chamber view, GLS was averaged from the remaining chamber views. The apical 4-chamber view was available for strain analysis in 1141 participants; the apical 2-chamber view was available for strain analysis in 813 participants; and the apical 3-chamber view was available for strain analysis in 609 participants. Hence, all 3 apical projections were available in 384 participants, 2 in 499 participants, and 1 in 413 participants. Our laboratory has previously demonstrated good intra-and interobserver agreement for GLS with a small bias (mean difference ±1.96 SDs was 0.1±1.6% for the intraobserver analysis and −0.8±2.0% for the interobserver analysis). 6 All analyses were performed by 1 investigator, who was blinded to all other information.
Follow-Up and Outcome
Participants were followed from the examination in 2001 through 2003 until April 2013 or time of event. The primary end point was defined as cardiovascular death (CVD) or admission because of either incident HF or acute myocardial infarction (AMI). The end points in the Copenhagen City Heart Study were obtained from the Danish National Board of Health's National Patient Registry using International Classification of Diseases-Tenth Revision codes and are described in more detail elsewhere. [15] [16] [17] [18] In addition, followup data on CVD was collected from the National Danish Causes of Death Registry. CVD was defined as International Classification of Diseases-Tenth Revision codes I00-I99. Follow-up was 100%.
Statistical Analysis
Baseline characteristics across GLS quartiles were compared with trend tests using linear regression for continuous Gaussian distributed variables, by an extension of the Wilcoxon rank-sum test 22 for continuous non-Gaussian distributed variables, and by χ 2 test for trend for proportions. Rates of all events were calculated as the number of events divided by person-time at risk and were stratified by quartiles of GLS. Figures 2 through 5 were constructed using a Poisson model to estimate incidence rates. Hazard ratios (HRs) were calculated by Cox proportional hazards regression analyses. Harrell's C statistics 23 were obtained from univariable Cox proportional hazards regression models to test the prognostic performance of GLS for predicting each end point. Multivariable Cox proportional hazards regression models were performed with an incremental increase in confounding variables included. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, heart rate, hypertension, diabetes mellitus, previous ischemic heart disease, systolic BP, and pro-BNP (>150 pmol/L). Model 3 is adjusted for the same variables as model 2 and additionally for LVEF (<50%), LVMI, LV dimension, deceleration time, left atrium dimension, and E/e′. Non-Gaussian distributed continuous variables (LVMI and E/e′) were categorized into quartiles when included in the models. Likewise, LVEF and proBNP were included in the multivariable Cox regression models as dichotomous variables. Cumulative survival curves were established by the Kaplan-Meier method and displayed in Figures I and II in the Data Supplement. The assumptions of proportional hazards in the models were tested based on the Schoenfeld residuals. Predictive models for predicting the risk of future cardiovascular mortality and morbidity were constructed using logistic regression. Reclassification analysis was used to assess the continuous net reclassification improvement (NRI) 24 when adding GLS to the significant clinical predictors from the Framingham Risk Score, 12 the SCORE risk chart, 13 and a modified version of the ACC/AHA Pooled Cohort Equation.
14 A P value ≤0.05 in 2-sided test was considered statistically significant. All analyses were performed with STATA Statistics/Data analysis, SE 12.0 (StataCorp, TX).
Results
Mean age of the study sample was 57.0±16.2 years, and 42% were male (Table 1) . During follow-up (median, 11.0 years; interquartile range, 9.9-11.2 years), 78 (6.0%) participants were admitted because of HF, 43 (3.3%) participants were admitted with an AMI, and 74 (5.7%) participants died because of cardiovascular causes. The composite outcome was reached by 149 (11.5%) participants. Lower GLS was associated with older age, male sex, higher systolic and diastolic BP, higher heart rate, higher body mass index, higher prevalence of ischemic heart disease, higher proportion of smokers, and higher cholesterol levels. Lower GLS was also associated with lower LVEF, larger LVMI, larger left atrial dimension, longer deceleration time, and higher E/e′.
GLS and Long-Term Outcome
The risk of the composite outcome of AMI, HF, or CVD was higher with lower quartile of the GLS (Table 2 and Figure 2 ) and was ≈3× as high in the first quartile compared with that in the fourth quartile (first quartile versus fourth quartile HR, In multivariable models adjusting for age, sex, heart rate, hypertension, diabetes mellitus, previous ischemic heart disease, systolic BP, proBNP, LVEF, LVMI, LV dimension, deceleration time, left atrium dimension, and E/e′, GLS remained an independent predictor of the composite end point, HF alone, and AMI alone, but not of CVD (Table 3) . Similar point estimates were found when restricting the population to only A indicates peak transmitral late diastolic inflow velocity; AMI, acute myocardial infarction; BMI, body mass index; DT, deceleration time of early diastolic inflow; E, peak transmitral early diastolic inflow velocity; e′, average peak early diastolic longitudinal mitral annular velocity determined by color TDI; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at end diastole; LVMI, left ventricular mass index; and proBNP, pro B-type natriuretic peptide. Myocardial Deformation Predicts Outcome in the General Population include participants with a normal LVEF; however, GLS only remained a statistically significant independent predictor of AMI (Table I in 
Incremental Value of the GLS in Relation to Predicting Future Outcome in the General Population
The primary risk stratification models used for assessing risk of cardiovascular morbidity and mortality in the general population are currently the Framingham Risk score and the SCORE risk chart. We assessed the incremental value of adding GLS to the Framingham Risk score or the SCORE risk chart prediction models (age, sex, cholesterol, smoking status, and systolic BP). GLS provided incremental prognostic information with regard to predicting the composite end point (continuous NRI 0.234; 95% CI, 0.024-0.433) and incident HF (continuous NRI, 0.381; 95% CI, 0.175-0.690). In contrast, NT-proBNP (N-terminal proBNP) did not provide incremental value to the Framingham Risk score or the SCORE risk chart in predicting the composite end point (continuous NRI, −0.050; 95% CI, −0.274 to 0.245). Adding GLS to the Framingham Risk score or the SCORE risk chart, however, did not provide incremental prognostic information beyond the conventional prediction models with respect to AMI (continuous NRI, 0.176; 95% CI, −0.195 to 0.554) or CVD (continuous NRI, 0.003; 95% CI, −0.059 to 0.236). We also assessed the incremental value of adding GLS to a modified version of the ACC/AHA Pooled Cohort Equation (age, sex, cholesterol, smoking status, systolic BP, hypertension and diabetes mellitus), where race was not included because participants in the present study only consisted of whites. Nevertheless, GLS provided incremental prognostic information with regard to predicting the composite end point (continuous NRI, 0.223; 95% CI, 0.023-0.427), and incident HF (continuous NRI, 0.375; 95% CI, 0.170-0.682), however, did not provide incremental prognostic information beyond the risk factors included in the modified ACC/AHA Pooled Cohort Equation with 
GLS, Long-Term Outcome, and Gender
Sex modified the relationship between GLS and the composite outcome ( Figure 2 and Table 3 ) and incident HF alone ( Figure 3 and Table 3 ), such that GLS was a stronger predictor of these outcomes in men compared with that in women (Tables 4 and 5 ; Figure II in the Data Supplement). After multivariable adjustment, GLS remained an independent predictor of the composite end point and incident HF in men but not in women (Table 4) . Sex did not significantly modify the relationship between GLS and AMI or CVD (Figures 4 and 5 and Table 3 ; Figure II in the Data Supplement). Similar results were found when restricting our analysis to Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, heart rate, hypertension, diabetes mellitus, previous ischemic heart disease, systolic blood pressure, and pro-BNP (>150 pmol/L). Model 3 is adjusted for the same variables as Model 2 and additionally for left ventricular (LV) ejection fraction (<50%), LV mass index, LV dimension, deceleration time, left atrium dimension, and E/e′. AMI indicates acute myocardial infarction; CI, confidence interval; E, peak transmitral early diastolic inflow velocity; e′, average peak early diastolic longitudinal mitral annular velocity determined by color TDI; HF, heart failure; GLS, global longitudinal strain; and proBNP, pro B-type natriuretic peptide. Model 1 is adjusted for age. Model 2 is adjusted for age, heart rate, hypertension, diabetes mellitus, previous ischemic heart disease, systolic blood pressure, and pro-BNP (>150 pmol/L). Model 3 is adjusted for the same variables as Model 2 and additionally for left ventricular (LV) ejection fraction (<50%), LV mass index, LV dimension, deceleration time, left atrium dimension, and E/e′. AMI indicates acute myocardial infarction; CI, confidence interval; E, peak transmitral early diastolic inflow velocity; e′, average peak early diastolic longitudinal mitral annular velocity determined by color TDI; HF, heart failure; GLS, global longitudinal strain; and proBNP, pro B-type natriuretic peptide. Myocardial Deformation Predicts Outcome in the General Population only include participants with normal LVEF (Tables II and  III in the Data Supplement) . Baseline clinical characteristics for the participants stratified according to sex are displayed in Table 6 .
Table 4. GLS as a Predictor of Long-Term Outcome in Men From General Population (n=549)
Composite End
Discussion
In this prospective study of a general population sample who underwent comprehensive echocardiography with GLS assessment and long-term outcome ascertainment, we demonstrate Model 1 is adjusted for age. Model 2 is adjusted for age, heart rate, hypertension, diabetes mellitus, previous ischemic heart disease, systolic blood pressure, and pro-BNP (>150 pmol/L). Model 3 is adjusted for the same variables as Model 2 and additionally for left ventricular (LV) ejection fraction (<50%), LV mass index, LV dimension, deceleration time, left atrium dimension, and E/e′. AMI indicates acute myocardial infarction; CI, confidence interval; E, peak transmitral early diastolic inflow velocity; e′, average peak early diastolic longitudinal mitral annular velocity determined by color TDI; HF, heart failure; GLS, global longitudinal strain; and proBNP, pro B-type natriuretic peptide. the following: (1) impaired cardiac function as assessed by GLS is a significant predictor of incident HF, AMI, or CVD, independent of clinical and other echocardiographic predictors. (2) GLS provides incremental prognostic value in predicting the composite cardiovascular outcome and incident HF alone beyond the Framingham Risk score, the SCORE risk chart, and the modified ACC/AHA Pooled Cohort Equation. (3) GLS seems to be a superior predictor of cardiovascular outcomes in men compared with that in women.
GLS provides a sensitive measure of LV function and appears reduced despite preserved LVEF in several cardiovascular risk conditions, such as advancing age, 3 hypertension, 4 diabetes mellitus, 5 stable angina, 6 renal dysfunction, 7 and obesity. 8 Furthermore, GLS has prognostic value in patients in a range of cardiovascular disorders, including AMI 25 and HF with reduced 11, 26 and preserved LVEF, 27 and also recently in the general population.
9,10,28 However, previous studies assessing the prognostic significance of GLS in the general population A indicates peak transmitral late diastolic inflow velocity; AMI, acute myocardial infarction; BMI, body mass index; DT, deceleration time of early diastolic inflow; E, peak transmitral early diastolic inflow velocity; e′, average peak early diastolic longitudinal mitral annular velocity determined by color TDI; eGFR, estimated glomerular filtration rate; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; and proBNP, pro B-type natriuretic peptide. Myocardial Deformation Predicts Outcome in the General Population have been limited by relatively short follow-up time (≈5 years), 9, 10, 28 particularly as current risk models assess cardiovascular risk over a 10-year period. Russo et al 9 studied 708 participants from the general population with 58 total cardiovascular events (AMI, ischemic strokes, and vascular deaths) over 4.8-year follow-up and found that GLS was a strong and independent predictor of this composite outcome. 9 The authors did not have sufficient power to assess the association between GLS and the individual end points and did not assess the usefulness of GLS to predict incident HF. Importantly, incident HF was the end point most strongly associated with impaired GLS. Cheng et al 10 found GLS to be an independent predictor of their composite coronary artery disease outcome (fatal or nonfatal AMI, coronary insufficiency, and angina pectoris). Notably, these investigators did not assess if this association was because of the association between GLS and stable coronary artery disease or AMI because GLS has previously been shown to be a strong diagnostic tool to assess risk of stable coronary artery disease in persons with a normal LVEF. 6 We found GLS to be an independent predictor of AMI, whichalthough in agreement with the ischemic event composite outcomes in the analyses of Russo et al 9 and Cheng et al 10 -is also one of the first demonstrations of the prognostic utility of GLS to assess risk of AMI specifically in the general population. Importantly, however, although GLS was an independent predictor of AMI in our study, it did not provide incremental prognostic value beyond the Framingham Risk score, the SCORE risk chart, or the ACC/AHA Pooled Cohort Equation.
In contrast, GLS was an independent predictor of incident HF and provided incremental prognostic information beyond the Framingham Risk score, the SCORE risk chart, and the ACC/ AHA Pooled Cohort Equation for this end point. Hence, in the general population, GLS has a higher specificity of detecting early LV systolic dysfunction, which increases the risk of HF as compared with that of AMI. This is in accordance with previous findings demonstrating that early systolic dysfunction determined by reduced myocardial systolic velocity (TDI s′) is a strong predictor of HF, whereas a reduced diastolic function as determined by a reduced early diastolic relaxation velocity (TDI e′) is a strong predictor of AMI. 17 In addition, it should be noted that the Framingham Risk score, the SCORE risk chart, and the ACC/AHA Pooled Cohort Equation all are calibrated to predict risk of ischemic cardiovascular events, which might also explain the finding that GLS did not provide incremental prognostic information regarding risk of AMI and CVD when added to the known risk factors. Cheng et al 10 found that circumferential strain was superior to GLS in predicting incident HF in their general population cohort because GLS was not an independent predictor of HF after multivariable adjustment. This discrepancy between our studies might be because of differences in the populations studied. The population included in the study by Cheng et al 10 was ≈10 years older (66 versus 57 years), and the prevalence of hypertension was almost twice as high (59% versus 37.8%) when compared with those of our population. Studies have demonstrated that patients with hypertension have impaired GLS and an accompanied exaggerated circumferential strain, [29] [30] [31] likely because of impairment of the right-handed helix-oriented subendocardial longitudinal fibers with resulting failure to fully counterbalance the subepicardial left-handed helix fiber shortening, which leads to increased circumferential deformation. 2, 25, 29, 30, 32 Hence, the older age and higher prevalence of hypertension in Cheng et al's 10 study sample may have resulted in a significant proportion of participants with compensatory increase in circumferential deformation such that a decrease in circumferential strain represents more pronounced cardiac dysfunction and was a stronger predictor of incident HF than GLS. 10 Unfortunately, we were not able to assess circumferential strain in the current cohort. However, the bidirectional nature of circumferential strain in the progression of an ailing heart might be the main reason why so conflicting results have been published in regard to the prognostic utility of circumferential strain 11 because the prognostic utility is largely dependent on the study population examined. In contrast, GLS decreases monotonically with progressive cardiac dysfunction, regardless of study population, which might explain why this marker consistently is found to be among the best echocardiographic markers to predict outcome in various patient populations. 11, [25] [26] [27] Interestingly, we found that GLS was not as predictive of cardiovascular morbidity and mortality in women as in men, particularly for the composite end point and incident HF where the interactions were found to be statistically significant. We have previously seen similar trends in a large population of 1065 patients with HF with reduced ejection fraction, 11 where GLS was found not to be a univariable predictor of mortality in women, but in men, GLS was found to be the strongest echocardiographic predictor of mortality. 11 It is known that women have a significantly lower amount of cardiac muscle mass as measured by LVMI 33, 34 and lower volumetric measurements. 20 The fact that women have a lower cardiac muscle mass and, therefore, less speckles to track might make 2-dimensional speckle tracking echocardiography a less accurate method of assessing cardiac function in women than in men. Systolic function as determined by LVEF 35, 36 and GLS 37 is higher in women than in men, a finding replicated in our study. Notably, only AMI events were significantly more frequent in men than in women, and the only outcome that seemed more frequent in women than in men was CVD, although not statistically significantly different. The higher proportion of women experiencing CVD might explain why GLS was not a univariable predictor of this end point when assessed in the whole cohort, but only in men, because GLS seems to be a less sensitive predictor of all outcomes in women. Besides the differences in cardiac structure and function, none of the differences in clinical characteristics displayed in Table 6 explain the difference in the prognostic capability of GLS for men and women. Women demonstrate a greater degree of concentric remodeling and greater preservation of LV systolic function in the face of increased afterload, 38 which may be related to sex-specific differences in physiology and hormone status, 39 which might also explain the difference seen in HF phenotype between men and women, where HF with preserved ejection fraction is much more prevalent in women, whereas HF with reduced LVEF is more common in men. 40 Despite the fact that sex has been found to modify the effect of GLS and outcome in 2 independent cohorts, these findings should still be considered explanatory and hypothesis generating. Myocardial Deformation Predicts Outcome in the General Population A major strength of the present prospective study is the community-based design of a large homogenous population of men and women across a broad range of ages, with complete long-term follow-up. However, the study sample was primarily white, which limits the generalizability of our findings to other races and ethnicities. Several statistical tests were performed in the present study, and no adjustments for multiple comparisons were performed. Parasternal short-axis views were not obtained in the present study, which made it impossible to assess circumferential strain. Unfortunately, we only assessed the association between low GLS and incident HF and were not able to assess whether this association was derived from incident HF with preserved ejection fraction or HF with reduced ejection fraction. The present analysis only includes GLS measured from echocardiograms obtained at 1 time point. It would be interesting to assess whether changes in GLS improves risk stratification in the general population; however, we do not have echocardiographic data for participants from 2 (or more) time points at the current moment. Whether high-sensitivity troponin adds complementary information to GLS would have been interesting to determine in the present study; however, unfortunately, high-sensitivity troponin was not available. Finally, GLS was not assessed in 858 participants (39.8%) because of low frame rate and inadequate images for 2-dimensional speckle tracking analysis. However, these images were obtained between 2001 and 2003 with outdated ultrasound systems (Vivid 5; GE Healthcare); hence, this proportion would be substantially lower using more recent ultrasound systems.
Conclusion
In the general population, GLS is an independent predictor of cardiovascular morbidity and mortality. GLS provides incremental prognostic information over and above current risk stratification models for a composite cardiovascular end point and for HF specifically. The prognostic utility of GLS seems to be stronger in men compared with that in women.
